biotechpharmaceuticals1.695 min read
"VTYX Stock Plummets as Psoriasis Treatment Trials Fail"
2 years ago•Source: Investor's Business Daily
Biotechpharmaceuticals News
The latest biotechpharmaceuticals stories, summarized by AI
Featured Biotechpharmaceuticals Stories
View original source
0.535 min•2 years ago
Nuvalent Raises $300M in Public Stock Offering
Cancer biotech company Nuvalent has announced a $300 million public offering of its common stock following positive Phase I results for its ALK-selective tyrosine kinase inhibitor candidate, NVL-655, in ALK-positive non-small cell lung cancer patients, with a 39% objective response rate observed in evaluable patients.
More Biotechpharmaceuticals Stories
No articles found.